Search and Contain: Impact of an Integrated Genomic and Epidemiological Surveillance and Response Program for Control of Carbapenemase-producing Enterobacterales.
antimicrobial resistance
carbapenemase-producing Enterobacterales
genomics
infection control
public health surveillance
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
06 12 2021
06 12 2021
Historique:
received:
10
03
2020
accepted:
08
07
2020
pubmed:
15
7
2020
medline:
15
3
2022
entrez:
15
7
2020
Statut:
ppublish
Résumé
Multiresistant organisms (MROs) pose a critical threat to public health. Population-based programs for control of MROs such as carbapenemase-producing Enterobacterales (CPE) have emerged and evaluation is needed. We assessed the feasibility and impact of a statewide CPE surveillance and response program deployed across Victoria, Australia (population 6.5 million). A prospective multimodal intervention including active screening, carrier isolation, centralized case investigation, and comparative pathogen genomics was implemented. We analyzed trends in CPE incidence and clinical presentation, risk factors, and local transmission over the program's first 3 years (2016-2018). CPE case ascertainment increased over the study period to 1.42 cases/100 000 population, linked to increased screening without a concomitant rise in active clinical infections (0.45-0.60 infections/100 000 population, P = .640). KPC-2 infection decreased from 0.29 infections/100 000 population prior to intervention to 0.03 infections/100 000 population in 2018 (P = .003). Comprehensive case investigation identified instances of overseas community acquisition. Median time between isolate referral and genomic and epidemiological assessment for local transmission was 11 days (IQR, 9-14). Prospective surveillance identified numerous small transmission networks (median, 2; range, 1-19 cases), predominantly IMP and KPC, with median pairwise distance of 8 (IQR, 4-13) single nucleotide polymorphisms; low diversity between clusters of the same sequence type suggested genomic cluster definitions alone are insufficient for targeted response. We demonstrate the value of centralized CPE control programs to increase case ascertainment, resolve risk factors, and identify local transmission through prospective genomic and epidemiological surveillance; methodologies are transferable to low-prevalence settings and MROs globally.
Sections du résumé
BACKGROUND
Multiresistant organisms (MROs) pose a critical threat to public health. Population-based programs for control of MROs such as carbapenemase-producing Enterobacterales (CPE) have emerged and evaluation is needed. We assessed the feasibility and impact of a statewide CPE surveillance and response program deployed across Victoria, Australia (population 6.5 million).
METHODS
A prospective multimodal intervention including active screening, carrier isolation, centralized case investigation, and comparative pathogen genomics was implemented. We analyzed trends in CPE incidence and clinical presentation, risk factors, and local transmission over the program's first 3 years (2016-2018).
RESULTS
CPE case ascertainment increased over the study period to 1.42 cases/100 000 population, linked to increased screening without a concomitant rise in active clinical infections (0.45-0.60 infections/100 000 population, P = .640). KPC-2 infection decreased from 0.29 infections/100 000 population prior to intervention to 0.03 infections/100 000 population in 2018 (P = .003). Comprehensive case investigation identified instances of overseas community acquisition. Median time between isolate referral and genomic and epidemiological assessment for local transmission was 11 days (IQR, 9-14). Prospective surveillance identified numerous small transmission networks (median, 2; range, 1-19 cases), predominantly IMP and KPC, with median pairwise distance of 8 (IQR, 4-13) single nucleotide polymorphisms; low diversity between clusters of the same sequence type suggested genomic cluster definitions alone are insufficient for targeted response.
CONCLUSIONS
We demonstrate the value of centralized CPE control programs to increase case ascertainment, resolve risk factors, and identify local transmission through prospective genomic and epidemiological surveillance; methodologies are transferable to low-prevalence settings and MROs globally.
Identifiants
pubmed: 32663248
pii: 5871379
doi: 10.1093/cid/ciaa972
pmc: PMC8662772
doi:
Substances chimiques
Bacterial Proteins
0
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3912-e3920Subventions
Organisme : National Health and Medical Research Council
ID : GNT1149991
Organisme : Australian Government Research Training Program scholarships
Organisme : Microbiological Diagnostic Unit Public Health Laboratory
Organisme : Victorian Government
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Clin Microbiol Rev. 2018 Feb 14;31(2):
pubmed: 29444952
J Hosp Infect. 2017 Jan;95(1):3-45
pubmed: 27890334
Euro Surveill. 2019 Sep;24(38):
pubmed: 31552821
Antimicrob Agents Chemother. 2015 Jul;59(7):4059-66
pubmed: 25918153
Clin Microbiol Infect. 2017 Jul;23(7):470-475
pubmed: 28143787
J Hosp Infect. 2019 Oct;103(2):156-159
pubmed: 31039383
Clin Microbiol Infect. 2017 Jan;23(1):48.e9-48.e16
pubmed: 27642178
J Hosp Infect. 2019 Feb;101(2):163-166
pubmed: 30102948
Lancet Infect Dis. 2016 Mar;16(3):282-3
pubmed: 26774242
Infect Control Hosp Epidemiol. 2020 Jan;41(1):37-43
pubmed: 31637986
BMC Infect Dis. 2014 Oct 01;14:528
pubmed: 25270732
Clin Infect Dis. 2014 Mar;58(5):697-703
pubmed: 24304707
Lancet Infect Dis. 2011 May;11(5):355-62
pubmed: 21478057
J Clin Microbiol. 2019 Aug 26;57(9):
pubmed: 31315956
PeerJ. 2018 Jan 3;6:e4210
pubmed: 29312831
Nat Commun. 2020 Jan 24;11(1):466
pubmed: 31980604
Front Public Health. 2017 Dec 18;5:347
pubmed: 29326921
Euro Surveill. 2019 Feb;24(9):
pubmed: 30862330
Clin Infect Dis. 2005 Dec 1;41(11):1549-56
pubmed: 16267725
Infect Control Hosp Epidemiol. 2018 Jan;39(1):85-89
pubmed: 29241475
Emerg Infect Dis. 2014 Jul;20(7):1170-5
pubmed: 24959688
J Infect. 2016 Feb;72(2):152-60
pubmed: 26546855
Nat Microbiol. 2019 Nov;4(11):1919-1929
pubmed: 31358985
J Antimicrob Chemother. 2014 Mar;69(3):632-6
pubmed: 24155060